After multiple doses, mean IGF-1 levels remained above baseline for up to 28 days, with no serious adverse reactions reported establishing the GHRH-analogue backbone as capable of sustained, clinically meaningful GH and IGF-1 axis elevation
or symptoms of significant dehydration such as dizziness, reduced urination, or inability to keep fluids down
(verified owner) Rated 5 out of 5 Amy R
Its phase 2 data demonstrated substantial weight loss, and topline phase 3 results suggest the possibility of weight reduction approaching or exceeding that of earlier incretin-based pharmacotherapies
M., Pickin, K
Hear from our patients With 450,000+ patients, Medi-Weightloss has reached 10 million pounds lost improving health, reducing disease risk, and helping people live longer